rs11674184 — GREB1 GREB1 Estrogen-Responsive Endometriosis Variant

Intronic GREB1 variant at 2p25.1 where the T allele (GRCh38 reference) is associated with increased endometriosis risk; the G allele confers protection. Identified independently of the nearby rs13394619 GREB1 variant (r²=0.65 in Europeans — moderate LD, not redundant), with OR=1.13 and P=3×10⁻¹⁷ for all endometriosis and OR=1.16 (P=6×10⁻⁹) for stage 3/4 disease in the 2023 Rahmioglu Nature Genetics GWAS.

See your personal result for GREB1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GREB1 at 2p25.1 — A Second Independent Endometriosis Signal in the Estrogen Cofactor Gene

Endometriosis affects an estimated 10% of reproductive-age women and remains one of the most under-diagnosed causes of chronic pelvic pain and infertility. The condition is estrogen-dependent: ectopic lesions generate their own local estrogen supply through elevated aromatase activity, and this autocrine estrogen loop drives lesion proliferation and immune evasion. GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output11 GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output
Chadchan et al. Nature Communications, 2024.

rs11674184 is an intronic variant in GREB1 at chromosome 2p25.1 that was identified as a statistically independent endometriosis risk signal in the landmark 2023 Rahmioglu Nature Genetics multi-ancestry GWAS meta-analysis. Critically, it is not simply a proxy for the previously described rs13394619 GREB1 variant already in the GeneOps database: the two variants have r²=0.65 in European populations — moderate linkage disequilibrium, not the r²>0.8 threshold that would indicate redundancy. They tag different aspects of the GREB1 regulatory landscape.

The GRCh38 reference allele (T) is the risk allele here, with the less common G allele conferring protection. This is the reverse of the intuitive direction — the T allele at rs11674184 is common (~63% globally) and constitutes the risk-conferring genotype.

The Mechanism

GREB1 operates as a context-dependent steroid hormone cofactor. In normal endometrium during the secretory phase, GREB1 binds the progesterone receptor and promotes downstream decidualization targets including WNT4 and FOXO1A22 In normal endometrium during the secretory phase, GREB1 binds the progesterone receptor and promotes downstream decidualization targets including WNT4 and FOXO1A
Chadchan et al. 2024. In endometriotic lesions, where estrogen dominates, GREB1 switches roles to act as an estrogen receptor cofactor — amplifying estrogen-driven gene expression and ectopic cell proliferation. GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women33 GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women
Pellegrini et al. Fertility and Sterility, 2012. Mouse knockout models with GREB1 deletion show substantially reduced ectopic lesion volume and mass.

The intronic rs11674184 variant lies within c.901+577 of the GREB1 transcript. Its modest CADD score (~7.7) and low evolutionary constraint (GERP −0.61) suggest limited direct functional impact on the protein, consistent with a regulatory tag SNP. Fine-mapping of the GREB1 locus by Fung et al. 2015 (Human Reproduction)44 Fung et al. 2015 (Human Reproduction)
Fung et al. Fine mapping of GREB1 in endometriosis, 2015 identified multiple intronic variants at this locus with independent association signals, suggesting the region contains at least two distinct regulatory elements influencing GREB1 expression or splicing in endometrial tissue.

The Evidence

Rahmioglu et al. 2023 (Nature Genetics)55 Rahmioglu et al. 2023 (Nature Genetics) conducted the largest endometriosis GWAS to date, incorporating data from 23andMe and major biobanks across European and East Asian populations. rs11674184 reached genome-wide significance for all endometriosis (risk allele T: OR=1.13, 95% CI 1.10–1.15, P=3×10⁻¹⁷) and showed a stronger association for confirmed Stage III/IV disease (OR=1.16, P=6×10⁻⁹), consistent with the pattern seen for the nearby rs13394619 where the GREB1 locus effect is enriched in moderate-to-severe disease.

A small Greek case-control study (166 cases, 168 controls) by Matalliotaki et al. 2019 (Molecular Medicine Reports)66 Matalliotaki et al. 2019 (Molecular Medicine Reports)
Matalliotaki et al. 2019 found no association for rs11674184, which the authors acknowledged was "one of the most consistently associated SNPs with endometriosis in European ancestry populations." The non-significant result in this study is consistent with insufficient statistical power rather than a true null: the effect size (OR≈1.13) and a sample of 166 cases would require approximately 2,000+ cases to reach genome-wide significance. The Rahmioglu 2023 finding with many thousands of cases is authoritative on this point.

The T allele frequency shows marked ancestry stratification: approximately 0.62 in Europeans, 0.57 in East Asians, but only approximately 0.24 in African populations — meaning GG protective homozygotes are far more common in women of African ancestry (~58%) than in Europeans (~14%).

Practical Implications

Carrying T alleles at rs11674184 raises endometriosis susceptibility, with OR≈1.13 per allele across the full endometriosis phenotype and OR≈1.16 for Stage III/IV. As with all common GWAS variants, these are population-level probability shifts rather than deterministic predictions. The key actionable implication is recognizing and acting on symptoms promptly. Endometriosis diagnostic delay averages 7–9 years across many healthcare systems, driven by normalization of menstrual pain. Women carrying the TT genotype — with the highest common genetic load at this locus — have the strongest motivation to pursue early specialist evaluation rather than accepting pain as normal.

For TT carriers in whom fertility is a consideration, the particular enrichment of this variant's effect at Stage III/IV disease supports proactive ovarian reserve assessment: moderate-to-severe endometriosis, especially ovarian endometriomas, is the mechanism through which endometriosis most directly impairs fertility.

Interactions

rs13394619 (GREB1): The other replicated intronic GREB1 variant in the GeneOps database. The two variants have r²=0.65 in European populations — they share roughly 65% of their variance but are not redundant. Women carrying risk alleles at both rs11674184 (TT or GT) and rs13394619 (GG or AG) may represent a subgroup with elevated cumulative GREB1-pathway genetic load. No formal published study has tested the joint effect of both variants in the same sample; pending such analysis, the individual effects should be considered as partially overlapping but not identical signals.

For supervisor compound action proposal: women carrying the T risk allele at rs11674184 (TT or GT) AND the G risk allele at rs13394619 (GG or AG) carry both GREB1 locus signals simultaneously. The combined recommendation would be: lower threshold for specialist gynecological referral, earlier baseline ovarian reserve testing (AMH + antral follicle count), and proactive fertility counseling. Evidence level: moderate (both independently established at the GREB1 locus; combined effect inferred from consistent additive direction but LD of r²=0.65 means they partially overlap; formal joint analysis not yet published).

rs12700667 (7p15.2, HOXA locus): The other major replicated endometriosis GWAS locus, operating through regulation of HOXA10/HOXA11 — distinct biological pathway from GREB1. Both loci show independent additive effects on endometriosis risk in GWAS meta-analyses, both show stronger signals for Stage III/IV disease, and women carrying risk alleles at both may represent the highest-risk common-variant group identifiable today.

Genotype Interpretations

What each possible genotype means for this variant.

GG Protective Homozygote Normal

Two copies of the protective G allele — reduced genetic susceptibility to endometriosis at this GREB1 locus

You carry two copies of the G allele at rs11674184, meaning you do not carry the T risk allele associated with elevated endometriosis susceptibility at this GREB1 locus. The GG genotype is relatively uncommon in women of European descent (approximately 14%) but is more frequent in women of African ancestry (approximately 58%), reflecting the strong population stratification of this variant.

This result does not eliminate endometriosis risk — the condition is influenced by many genetic and environmental factors — but at this particular locus you carry the protective genotype. Standard symptom awareness remains important regardless of genotype.

TT Two Risk Alleles High Risk

Two copies of the T risk allele — highest genetic susceptibility at this GREB1 locus

GREB1 promotes estrogen-dependent proliferation of endometriotic lesions by acting as an estrogen receptor cofactor in ectopic tissue — directly amplifying the estrogen-driven transcriptional program that sustains lesion growth. Elevated GREB1 expression has been documented in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected controls. GREB1 knockout in mouse endometriosis models significantly reduces lesion volume and mass.

Carrying two T alleles places you at the higher end of the common genetic risk distribution for endometriosis at this GREB1 locus. rs11674184 was identified in the Rahmioglu 2023 multi-ancestry meta-analysis — the largest endometriosis GWAS published to date — with P=3×10⁻¹⁷ for all endometriosis. The Stage III/IV association (OR=1.16, P=6×10⁻⁹) aligns with the pattern seen across GREB1 locus variants.

This result is not diagnostic. Most TT women will not develop clinically significant endometriosis. However, it is a meaningful signal to factor into symptom monitoring and reproductive planning. The well-documented 7–9 year diagnostic delay for endometriosis in many healthcare systems is partially attributable to normalization of menstrual pain — knowing this genetic signal provides concrete motivation to pursue early evaluation rather than waiting for symptoms to escalate.

Note that a second GREB1 variant (rs13394619, G risk allele) is catalogued separately in GeneOps. These two variants are in moderate LD (r²=0.65 in Europeans) — they partially overlap but each captures independent variation at the GREB1 locus. A woman carrying TT at rs11674184 may or may not also carry G risk alleles at rs13394619; these are not equivalent measures of the same genetic effect.

GT One Risk Allele Carrier

One copy of the T risk allele — modestly elevated endometriosis susceptibility

GREB1 encodes an estrogen receptor cofactor that amplifies estrogen-driven gene expression in endometriotic lesions. The intronic rs11674184-T allele likely influences GREB1 expression or splicing in endometrial tissue; the precise molecular mechanism has not been fully resolved but is consistent with the regulatory complexity of the GREB1 locus demonstrated by fine-mapping studies.

This variant (rs11674184) is distinct from the previously catalogued rs13394619 GREB1 variant: the two share r²=0.65 in European populations — partial overlap but not redundancy. Each captures partially independent variation in GREB1 regulatory biology.

The risk conferred by heterozygosity is real but modest in absolute terms. Endometriosis prevalence is approximately 10% in reproductive-age women; one T allele shifts that estimate upward modestly, with the largest estimated effect on surgically confirmed moderate-to-severe disease. Diagnostic delay averaging 7–9 years in many healthcare systems makes symptom awareness and low referral thresholds the most actionable response to this genetic signal.